

**Section of Cardiovascular Research  
Department of Medicine, Baylor College of Medicine  
(1 July 2017–30 June 2018)**

**A. Publications**

1. Power MC, Rawlings A, Sharrett AR, Bandeen-Roche K, Coresh J, **Ballantyne CM**, Pokharel Y, Michos ED, Penman A, Alonso A, Knopman D, Mosley TH, Gottesman RF. Association of midlife lipids with 20-year cognitive change: a cohort study. *Alzheimers Dement* 2018;14:167–177.
2. Fashanu OE, Norby FL, Aguilar D, **Ballantyne CM**, **Hoogeveen RC**, Chen LY, Soliman EZ, Alonso A, Folsom AR. Galectin-3 and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J* 2017;192:19–25.
3. Navar AM, Wang TY, Li S, Robinson JG, Goldberg AC, **Virani S**, Roger VL, Wilson PWF, Elassal J, Lee LV, Peterson ED. Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. *Am Heart J* 2017;193:84–92.
4. Yong CM, Liu Y, Apruzzese P, Doros G, Cannon CP, Maddox TM, Gehi A, Hsu JC, Lubitz SA, **Virani S**, Turakhia MP; ACC PINNACLE Investigators. Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: a report from the American College of Cardiology NCDR PINNACLE registry. *Am Heart J* 2018;195:50–59.
5. Hess PL, Kennedy K, Cowherd M, **Virani SS**, Masoudi FA, Navar AM, Yeh RW, Ho PM, Maddox TM. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: an NCDR Research to Practice (R2P) project. *Am Heart J* 2018;195:151–152.
6. Garg PK, Bartz TM, Norby FL, Jorgensen NW, McClelland RL, **Ballantyne CM**, Chen LY, Gottdiener JS, Greenland P, **Hoogeveen R**, Jenny NS, Kizer JR, Rosenson RS, Soliman EZ, Cushman M, Alonso A, Heckbert SR. Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: findings from 3 cohorts. *Am Heart J* 2018;197:62–69.
7. Lowenstern A, Li S, Navar AM, **Virani S**, Lee LV, Louie MJ, Peterson ED, Wang TY. Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. *Am Heart J* 2018;200:118–124.
8. **Ballantyne CM**, Shah S, Sapre A, Ashraf TB, Tobias SC, Sahin T, Ye P, Dong Y, Sheu WH, Kang DH, Ferreira Rossi PR, Moiseeva Y, Briones IR, Johnson-Levonas AO, Mitchel YB. A multiregional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol. *Am J Cardiol* 2017;120:569–576.
9. Khan MR, Kayani WT, Ahmad W, Hira RS, **Virani SS**, Hamzeh I, Jneid H, Lakkis N, Alam M. Meta-analysis of comparison of 5-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery in the era of drug-eluting stents. *Am J Cardiol* 2017;120:1514–1520.
10. Fretz A, McEvoy JW, Rebholz CM, Ndumele CE, Florido R, **Hoogeveen RC**, **Ballantyne CM**, Selvin E. Relation of lifestyle factors and Life's Simple 7 score to temporal reduction in troponin levels measured by a high-sensitivity assay (from the Atherosclerosis Risk in Communities Study). *Am J Cardiol* 2018;121:430–436.

11. McCullough PA, **Ballantyne CM**, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH. Efficacy and safety of alirocumab in high-risk patients with clinical atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia (from 5 placebo-controlled ODYSSEY trials). *Am J Cardiol* 2018;121:940–948.
12. Tibuakuu M, Kianoush S, DeFilippis AP, McEvoy JW, Zhao D, Guallar E, **Ballantyne CM, Hoogeveen RC**, Blaha MJ, Michos ED. Usefulness of lipoprotein-associated phospholipase A2 activity and C-reactive protein in identifying high-risk smokers for atherosclerotic cardiovascular disease (from the Atherosclerosis Risk in Communities Study). *Am J Cardiol* 2018;121:1056–1064.
13. **Trial J, Cieslik KA**. Changes in cardiac resident fibroblast physiology and phenotype in aging. *Am J Physiol Heart Circ Physiol* 2018 [Epub ahead of print].
14. Vart P, Matsushita K, Rawlings AM, Selvin E, Crews DC, Ndumele CE, **Ballantyne CM**, Heiss G, Kucharska-Newton A, Szklo M, Coresh J. SES, heart failure, and N-terminal pro-B-type natriuretic peptide: the Atherosclerosis Risk in Communities Study. *Am J Prev Med* 2018;54:229–236.
15. Tang W, Yao L, **Hoogeveen RC**, Alonso A, Couper DJ, Lutsey PL, Steenson CC, Guan W, Hunter DW, Lederle FA, Folsom AR. The association of biomarkers of inflammation and extracellular matrix degradation with the risk of abdominal aortic aneurysm: the ARIC Study. *Angiology* 2018 [Epub ahead of print].
16. Smith MW, Brown C, **Virani SS**, Weir CR, Petersen LA, Kelly N, Akeroyd J, Garvin JH. Incorporating guideline adherence and practice implementation issues into the design of decision support for beta-blocker titration for heart failure. *Appl Clin Inform* 2018;9:478–489.
17. Vaughan EM, Moreno JP, Hyman D, Chen TA, **Foreyt JP**. Efficacy of oral versus insulin therapy for newly diagnosed diabetes in low-income settings. *Arch Gen Intern Med* 2017;1:17–22.
18. Lockyer P, Mao H, Fan Q, Li L, LYu-Lee L, Eissa NT, Patterson C, **Xie L, Pi X**. LRP1-dependent BMPER signaling regulates lipopolysaccharide-induced vascular inflammation. *Arterioscler Thromb Vasc Biol* 2017;37:1524–1535.
19. Zhou Y, Cardenas JC, Qin S, Trist A, Li T, Garcia R, **Cruz MA**, Moake J, Tian Q, Frazier O, Dong JF, Nascimbene A. quantification of von Willebrand factor cleavage by ADAMTS-13 in patients supported by left ventricular assist devices. *ASAIO J* 2017;63:849–853.
20. **Agarwala A**, Pokharel Y, **Saeed A, Sun W, Virani SS, Nambi V**, Ndumele C, Shahar E, Heiss G, Boerwinkle E, Konety S, **Hoogeveen RC, Ballantyne CM**. The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. *Atherosclerosis* 2017;262:131–137.
21. Puri R, **Ballantyne CM, Hoogeveen RC**, Shao M, Barter P, Libby P, Chapman MJ, Erbel R, Arsenault BJ, Raichlen JS, Nissen SE, Nicholls SJ. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. *Atherosclerosis* 2017;263:137–144.
22. Amrock SM, Duell PB, Knickelbine T, Martin SS, O'Brien EC, Watson KE, Mitri J, Kindt I, Shrader P, Baum SJ, Hemphill LC, Ahmed CD, Andersen RL, Kullo IJ, McCann D, Larry JA, Murray MF, Fishberg R, Guyton JR, Wilemon K, Roe MT, Rader DJ, **Ballantyne CM**, Underberg JA, Thompson P, Duffy D, Linton MF, Shapiro MD, Moriarty PM, Knowles JW, Ahmad ZS. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. *Atherosclerosis* 2017;267:19–26.
23. Garg PK, Norby FL, Polfus LM, Boerwinkle E, Gibbs RA, Grove ML, Folsom AR, Garimella PS, Matsushita K, **Hoogeveen RC, Ballantyne CM**. Lipoprotein-associated

- phospholipase A2 and risk of incident peripheral arterial disease: findings from the Atherosclerosis Risk in Communities study (ARIC). *Atherosclerosis* 2017;268:12–18.
24. Kubota Y, Folsom AR, **Ballantyne CM**, Tang W. Lipoprotein(a) and abdominal aortic aneurysm risk: the Atherosclerosis Risk in Communities study. *Atherosclerosis* 2017;268:63–67.
  25. Valero-Elizondo J, Hong JC, Spatz ES, Salami JA, Desai NR, Rana JS, Khera R, **Virani SS**, Blankstein R, Blaha MJ, Nasir K. Persistent socioeconomic disparities in cardiovascular risk factors and health in the United States: Medical Expenditure Panel Survey 2002–2013. *Atherosclerosis* 2018;269:301–305.
  26. Ogunmoroti O, Michos ED, Aronis KN, Salami JA, Blankstein R, **Virani SS**, Spatz ES, Allen NB, Rana JS, Blumenthal RS, Veledar E, Szklo M, Blaha MJ, Nasir K. Life's Simple 7 and the risk of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis* 2018;275:174–181.
  27. **Ballantyne CM**, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. *Atherosclerosis* 2018 [Epub ahead of print].
  28. **Vijayan KV**. Myosin IIa signal von Willebrand factor release. *Blood* 2018;131:592–593.
  29. White DL, **Hoogeveen RC**, Chen L, Richardson P, Ravishankar M, Shah P, Tinker L, Rohan T, Whitsel EA, El-Serag HB, Jiao L. A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. *Cancer Med* 2018;7:2180–2191.
  30. **Saeed A, Ballantyne CM**. Bempedoic acid (ETC-1002): a current review. *Cardiol Clin* 2018;36:257–264.
  31. Wang Q, Quick AP, Cao S, Reynolds J, Chiang DY, Beavers D, **Li N**, Wang G, Rodney GG, Anderson ME, Wehrens XHT. Oxidized CaMKII (Ca<sup>2+</sup>/calmodulin-dependent protein kinase II) is essential for ventricular arrhythmia in a mouse model of Duchenne muscular dystrophy. *Circ Arrhythm Electrophysiol* 2018;11:e005682.
  32. Navar AM, Peterson ED, Li S, Robinson JG, Roger VL, Goldberg AC, **Virani S**, Wilson PWF, Nanna MG, Lee LV, Ellassal J, Wang TY. Prevalence and management of symptoms associated with statin therapy in community practice: insights from the PALM (Patient and Provider Assessment of Lipid Management) Registry. *Circ Cardiovasc Qual Outcomes* 2018;11:e004249.
  33. **Virani SS**, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, **Ballantyne CM**. Variation in lipid-lowering therapy use in patients with low-density lipoprotein cholesterol  $\geq 190$  mg/dl: insights from the National Cardiovascular Data Registry–Practice Innovation and Clinical Excellence Registry. *Circ Cardiovasc Qual Outcomes* 2018;11:e004652.
  34. Harrington JL, Ayers C, Berry JD, Omland T, Pandey A, Seliger SL, **Ballantyne CM**, Kulinski J, deFilippi CR, de Lemos JA. Sedentary behavior and subclinical cardiac injury: results from the Dallas Heart Study. *Circulation* 2017;136:1451–1453.
  35. **Nambi V**, Deswal A, **Ballantyne CM**. Prevention of "failure": is it a failure of prevention? *Circulation* 2018;137:106–108.
  36. Khera R, Hong JC, Saxena A, Arrieta A, **Virani SS**, Blankstein R, de Lemos JA, Krumholz HM, Nasir K. Burden of catastrophic health expenditures for acute myocardial infarction and stroke among uninsured in the United States. *Circulation* 2018;137:408–410.
  37. Florido R, Kwak L, Lazo M, **Nambi V**, Ahmed HM, Hegde SM, Gerstenblith G, Blumenthal RS, **Ballantyne CM**, Selvin E, Folsom AR, Coresh J, Ndumele CE. Six-year changes in physical activity and the risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2018;137:2142–2151.

38. Benjamin EJ, **Virani SS**, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. *Circulation* 2018;137:e67–e492.
39. Yao C, Veleva T, Scott L Jr, Cao S, Li L, Chen G, Jeyabal P, Pan X, Alsina KM, Abu-Taha I, Ghezalbash S, Reynolds CL, Shen YH, LeMaire SA, Schmitz W, Müller FU, El-Armouche A, Eissa NT, Beeton C, Nattel S, Wehrens XHT, Dobrev D, **Li N**. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. *Circulation* 2018 [Epub ahead of print].
40. Rehman H, Akeroyd JM, Ramsey D, Ahmed ST, Merchant AT, Navaneethan SD, Petersen LA, **Virani SS**. Facility-level variation in diabetes and blood pressure control in patients with diabetes: Findings from the Veterans Affairs national database. *Clin Cardiol* 2017;40:1055–1060.
41. Ndumele CE, Cobb L, Lazo M, Bello NA, Shah A, **Nambi V**, Blumenthal RS, Gerstenblith G, Solomon SD, **Ballantyne CM**, Selvin E, Coresh J. Weight history and subclinical myocardial damage. *Clin Chem* 2018;64:201–209.
42. Lo GH, McAlindon TE, Katz JN, Driban JB, Price LL, Eaton CB, Petersen NJ, **Ballantyne CM**, Suarez-Almazor ME. Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. *Clin Rheumatol* 2017;36:2121–2128.
43. Singh J, **Brunner G**, **Morrisett JD**, **Ballantyne CM**, Lumsden AB, Shah DJ, Decuzzi P. Patient-specific flow descriptors and normalized wall index in peripheral artery disease: a preliminary study. *Comput Methods Biomech Biomed Eng Imaging Vis* 2018;6:119–127.
44. Ahmed ST, Rehman H, Akeroyd JM, Alam M, Shah T, Kalra A, **Virani SS**. Premature coronary heart disease in South Asians: burden and determinants. *Curr Atheroscler Rep* 2018;20:6.
45. **Saeed A**, Dabhadkar K, **Virani SS**, **Jones PH**, **Ballantyne CM**, **Nambi V**. Cardiovascular disease prevention: training opportunities, the challenges, and future directions. *Curr Atheroscler Rep* 2018;20:35. [Correction: *Curr Atheroscler Rep* 2018;20:42]
46. Kampangkaew J, Pickett S, **Nambi V**. Advances in the management of dyslipidemia. *Curr Opin Cardiol* 2017;32:348–355.
47. LeBlanc ES, Pratley RE, Dawson-Hughes B, Staten MA, Sheehan PR, Lewis MR, Peters A, Kim SH, Chatterjee R, Aroda VR, Chadha C, Neff LM, Brodsky IG, Rosen C, Desouza CV, **Foreyt JP**, Hsia DS, Johnson KC, Raskin P, Kashyap SR, O'Neil P, Phillips LS, Rasouli N, Liao EP, Robbins DC, Pittas AG; D2d Research Group. Baseline characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: a contemporary prediabetes cohort that will inform diabetes prevention efforts. *Diabetes Care* 2018 [Epub ahead of print].
48. Vaughan EM, Johnston CA, Cardenas VJ, Moreno JP, **Foreyt JP**. Integrating CHWs as part of the team leading diabetes group visits: a randomized controlled feasibility study. *Diabetes Educ* 2017;43:589–599.
49. Andersen A, **Foreyt J**, Maine M, Cohn L. Eating disorders: a 25-year perspective. *Eat Disord* 2017;25:436–447.

50. Lai YC, **Li N**, Lawrence W, Wang S, Levine A, Burchhardt DM, Pautler RG, Valderrábano M, Wehrens XH, Anderson AE. Myocardial remodeling and susceptibility to ventricular tachycardia in a model of chronic epilepsy. *Epilepsia Open* 2018;3:213–223.
51. Matsushita K, Kwak L, Yang C, Pang Y, Ballew SH, Sang Y, **Hoogeveen RC**, Jaar BG, Selvin E, **Ballantyne CM**, Sharrett AR, Folsom AR, Heiss G, Coresh J, Hirsch AT. High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. *Eur Heart J* 2018 [Epub ahead of print].
52. Angelini A, **Pi X**, **Xie L**. Dioxygen and metabolism; dangerous liaisons in cardiac function and disease. *Front Physiol* 2017 Dec 12;8:1044.
53. Johnston CA, Moreno JP, Reichel B, **Foreyt JP**. Dissemination of a school-based obesity intervention for Mexican Americans: a randomized controlled trial. *Health Behavior Policy Review* 2017;4:454–466.
54. **Saeed A**, **Virani SS**. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. *Front Biosci (Landmark Ed)* 2018;23:1099–1112.
55. Klipp RC, **Li N**, Wang Q, Word TA, Sibrian-Vazquez M, Strongin RM, Wehrens XHT, Abramson JJ. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2. *Heart Rhythm* 2018;15:578–586.
56. Kocarnik JM, Richard M, Graff M, Haessler J, Bien S, Carlson C, Carty CL, Reiner AP, Avery CL, **Ballantyne CM**, LaCroix AZ, Assimes TL, Barbalic M, Pankratz N, Tang W, Tao R, Chen D, Talavera GA, Daviglius ML, Chirinos DA, Pereira R, Nishimura K, Buková P, Best LG, Luis Ambite J, Cheng I, Crawford DC, Hindorff LA, Fornage M, Heiss G, North KE, Haiman CA, Peters U, Le Marchand L, Kooperberg C. Discovery, fine-mapping, and conditional analyses of genetic variants associated with C-reactive protein in multiethnic populations using the MetaboChip in the Population Architecture using Genomics and Epidemiology (PAGE) study. *Hum Mol Genet* 2018 [Epub ahead of print].
57. Samad Z, Merchant AT, Narula JS, **Virani SS**. "All hands on deck": an imperative for tackling hypertension in South Asia. *Indian Heart J* 2017;69:430–431.
58. Arenas de Larriva AP, Norby FL, Chen LY, Soliman EZ, **Hoogeveen RC**, Arking DE, Loehr LR, Alonso A. Circulating ceruloplasmin, ceruloplasmin-associated genes, and the incidence of atrial fibrillation in the Atherosclerosis Risk in Communities study. *Int J Cardiol* 2017;241:223–228.
59. Chelu MG, **Li N**. Biomarkers (plasma trimethylamine-N-oxide) to predict atrial fibrillation: are we there yet? *Int J Cardiol* 2018 [Epub ahead of print].
60. Yousif A, Addison D, Lakkis N, Rosengart T, **Virani SS**, Birnbaum Y, Alam M. Use of cardiopulmonary pump support during coronary artery bypass grafting in the high-risk: a meta-analysis. *Ir J Med Sci* 2018;187:369–377.
61. Lloyd-Jones DM, Morris PB, **Ballantyne CM**, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr. 2017 focused update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol* 2017;70:1785–1822.
62. **Nambi V**, Bhatt DL. Primary prevention of atherosclerosis: time to take a selfie? *J Am Coll Cardiol* 2017;70:2992–2994.
63. **Saeed A**, **Nambi V**, **Sun W**, **Virani SS**, **Taffet G**, Deswal A, Selvin E, Matsushita K, Wagenknecht LE, **Hoogeveen R**, Coresh J, de Lemos JA, **Ballantyne CM**. Short-term global cardiovascular disease risk prediction in older adults. *J Am Coll Cardiol* 2018;71:2527–2536.

64. Navaneethan SD, **Virani SS**. Omega-3 fatty acids (fish oil) supplementation and albuminuria: not a slam dunk. *J Am Heart Assoc* 2017;6:e006020.
65. van Capelleveen JC, Bochem AE, Boekholdt SM, Mora S, **Hoogeveen RC, Ballantyne CM**, Ridker PM, **Sun W**, Barter PJ, Tall AR, Zwinderman AH, Kastelein JJP, Wareham NJ, Khaw KT, Hovingh GK. Association of high-density lipoprotein-cholesterol versus apolipoprotein A-I with risk of coronary heart disease: the European Prospective Investigation into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. *J Am Heart Assoc* 2017;6:e006636.
66. Aronis KN, Zhao D, **Hoogeveen RC**, Alonso A, **Ballantyne CM**, Guallar E, Jones SR, Martin SS, Nazarian S, Steffen BT, **Virani SS**, Michos ED. Associations of lipoprotein(a) levels with incident atrial fibrillation and ischemic stroke: the ARIC (Atherosclerosis Risk in Communities) Study. *J Am Heart Assoc* 2017;6:e007372.
67. Salami JA, Warraich HJ, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, **Virani SS**, Blankstein R, Khera A, Blaha MJ, Blumenthal RS, Katzen BT, Lloyd-Jones D, Krumholz HM, Nasir K. National trends in nonstatin use and expenditures among the US adult population from 2002 to 2013: Insights From Medical Expenditure Panel Survey. *J Am Heart Assoc* 2018;7:e007132.
68. Singh J, Valero-Elizondo J, Salami JA, Warraich HJ, Ogunmoroti O, Spatz ES, Desai N, Rana JS, **Virani SS**, Blankstein R, Blaha MJ, Nasir K. Favorable modifiable cardiovascular risk profile is associated with lower healthcare costs among cancer patients: the 2012-2013 Medical Expenditure Panel Survey. *J Am Heart Assoc* 2018;7:e007874.
69. Basra SS, Wang TY, Simon DN, Chiswell K, **Virani SS**, Alam M, **Nambi V**, Denktas AE, Deswal A, Bozkurt B, **Ballantyne CM**, Peterson ED, Jneid H. Ticagrelor use in acute myocardial infarction: insights from the National Cardiovascular Data Registry. *J Am Heart Assoc* 2018;7:e008125.
70. Kayani WT, **Ballantyne CM**. Improving outcomes after myocardial infarction in the US population. *J Am Heart Assoc* 2018;7:e008407.
71. Nanna MG, Navar AM, Wang TY, Mi X, **Virani SS**, Louie MJ, Lee LV, Goldberg AC, Roger VL, Robinson J, Peterson ED. Statin use and adverse effects among adults >75 years of age: insights from the Patient and Provider Assessment of Lipid Management (PALM) Registry. *J Am Heart Assoc* 2018;7:e008546.
72. Juraschek SP, Daya N, Appel LJ, Miller ER III, McEvoy JW, Matsushita K, **Ballantyne CM**, Selvin E. Orthostatic hypotension and risk of clinical and subclinical cardiovascular disease in middle-aged adults. *J Am Heart Assoc* 2018;7:e008884.
73. Miedema MD, Dardari ZA, Kianoush S, **Virani SS**, Yeboah J, Knickelbine T, Sandfort V, Rodriguez CJ, Nasir K, Blaha MJ. Statin eligibility, coronary artery calcium, and subsequent cardiovascular events according to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). *J Am Heart Assoc* 2018;7:e008920.
74. Pradhan S, Khatlani T, Nairn AC, **Vijayan KV**. The heterotrimeric G protein G $\beta_1$  interacts with the catalytic subunit of protein phosphatase 1 and regulates G protein coupled receptor signaling in platelets. *J Biol Chem* 2017;292:13133–13142.
75. Suh JH, Lai L, Nam D, Kim J, Jo J, **Taffet GE**, Kim E, Kaelber JT, Lee HK, **Entman ML**, Cooke JP, Reineke EL. Steroid receptor coactivator-2 (SRC-2) coordinates cardiomyocyte paracrine signaling to promote pressure overload-induced angiogenesis. *J Biol Chem* 2017;292:21643-21652.
76. Johnson KC, Bray GA, Cheskin LJ, Clark JM, Egan CM, **Foreyt JP**, Garcia KR, Glasser S, Greenway FL, Gregg EW, Hazuda HP, Hergenroeder A, Hill JO, Horton ES, Jakicic JM, Jeffery RW, Kahn SE, Knowler WC, Lewis CE, Miller M, Montez MG, Nathan DM,

- Patricio JL, Peters AL, Pi-Sunyer X, Pownall HJ, Reboussin D, Redmon JB, Steinberg H, Wadden TA, Wagenknecht LE, Wing RR, Womack CR, Yanovski SZ, Zhang P, Schwartz AV; Look AHEAD Study Group. The effect of intentional weight loss on fracture risk in persons with diabetes: results from the Look AHEAD randomized clinical trial. *J Bone Miner Res* 2017;32:2278–2287.
77. Yao H, He G, Chen C, Yan S, Lu L, Song L, **Vijayan KV**, Li Q, Xiong L, Miao X, Deng X. PAI1: a novel PP1-interacting protein that mediates human plasma's anti-apoptotic effect in endothelial cells. *J Cell Mol Med* 2017;21:2068–2076.
78. **Perrard XYD, Lian Z**, Bobotas G, Dicklin M, Maki K, **Wu H**. Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia. *J Clin Lipidol* 2017;11:1361–1371.
79. Pokharel Y, Tang Y, Bhardwaj B, Patel KK, Qintar M, O'Keefe JH Jr, Kulkarni KR, **Jones PH**, Martin SS, **Virani SS**, Spertus JA. Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study. *J Clin Lipidol* 2017;11:1458–1470.e4.
80. Bucheit JD, Helsing H, Nadpara P, **Virani SS**, Dixon DL. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. *J Clin Lipidol* 2018;12:367–374.e3.
81. **Saeed A, Virani SS, Jones PH, Ballantyne CM, Nambi V**. Case reports of proprotein convertase subtilisin kexin 9 (PCSK9) inhibition non-response. *J Clin Lipidol* 2018 [Epub ahead of print].
82. Navaneethan SD, Schold JD, Walther CP, Arrigain S, Jolly SE, **Virani SS**, Winkelmayr WC, Nally JV Jr. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. *J Clin Lipidol* 2018 [Epub ahead of print].
83. Federspiel JJ, Sueta CA, Kucharska-Newton AM, Beyhaghi H, Zhou L, **Virani SS**, Rodgers JE, Chang PP, Stearns SC. Antihypertensive adherence and outcomes among community-dwelling Medicare beneficiaries: the Atherosclerosis Risk in Communities Study. *J Eval Clin Pract* 2018;24:48–55.
84. Woodard LD, Adepoju OE, Amspoker AB, **Virani SS**, Ramsey DJ, Petersen LA, Jones LA, Kiefer L, Mehta P, Naik AD. Impact of patient-centered medical home implementation on diabetes control in the Veterans Health Administration. *J Gen Intern Med* 2018 [Epub ahead of print].
85. Houston DK, Neiberg RH, Miller ME, Hill JO, Jakicic JM, Johnson KC, Gregg EW, Hubbard VS, Pi-Sunyer X, Rejeski WJ, Wing RR, Bantle JP, Beale E, Berkowitz RI, Cassidy-Begay M, Clark JM, Coday M, Delahanty LM, Dutton G, Egan C, **Foreyt JP**, Greenway FL, Hazuda HP, Hergenroeder A, Horton ES, Jeffery RW, Kahn SE, Kure A, Knowler WC, Lewis CE, Martin CK, Michaels S, Montez MG, Nathan DM, Patricio J, Peters A, Pownall H, Regensteiner J, Steinburg H, Wadden TA, White K, Yanovski SZ, Zhang P, Kritchevsky SB. Physical function following a long-term lifestyle intervention among middle aged and older adults with type 2 diabetes: the Look AHEAD Study. *J Gerontol A Biol Sci Med Sci* 2017 [Epub ahead of print].
86. **Cieslik KA**, Sekhar RV, Granillo A, **Reddy A**, Medrano G, Pena Heredia C, **Entman ML**, Hamilton DJ, Li S, Reineke E, Gupte AA, Zhang A, **Taffet GE**. Improved cardiovascular function in old mice after N-acetyl cysteine and glycine supplemented diet: inflammation and mitochondrial factors. *J Gerontol A Biol Sci Med Sci* 2018 [Epub ahead of print].
87. Lam F, Da Q, Guillory B, **Cruz MA**. The binding of recombinant vimentin to P-selectin blocks neutrophil capture and rolling on platelets and endothelium. *J Immunol* 2018;200:1718–1726.
88. **Cieslik KA, Trial J, Entman ML**. Aicar treatment reduces interstitial fibrosis in aging mice: suppression of the inflammatory fibroblast. *J Mol Cell Cardiol* 2017;111:81–85.

89. Vaughan EM, Johnston CA, Hyman DJ, Hernandez DC, Hemmige V, **Foreyt JP**. Dual therapy appears superior to monotherapy for low-income individuals with newly diagnosed type 2 diabetes. *J Prim Care Community Health* 2017;8:305–311.
90. Brinton EA, **Ballantyne CM**, Guyton JR, Philip S, Doyle RT Jr, Juliano RA, Mosca L. Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR trial subanalysis. *J Womens Health (Larchmt)* 2018 [Epub ahead of print].
91. Hira RS, Vemulapalli S, Li Z, McCabe JM, Rumsfeld JS, Kapadia SR, Alam M, Jneid H, Don C, Reisman M, **Virani SS**, Kleiman NS. Trends and outcomes of off-label use of transcatheter aortic valve replacement: insights from the NCDR STS/ACC TVT Registry. *JAMA Cardiol* 2017;2:846–854.
92. Arrieta A, Hong JC, Khera R, **Virani SS**, Krumholz HM, Nasir K. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER Trial. *JAMA Cardiol* 2017;2:1369–1374.
93. Schwartz GG, **Ballantyne CM**, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, Kittelson J. Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes randomized clinical trial. *JAMA Cardiol* 2018;3:164–168.
94. Vazir A, Claggett B, Cheng S, Skali H, Shah A, Aguilar D, **Ballantyne CM**, Vardeny O, Solomon SD. Association of resting heart rate and temporal changes in heart rate with outcomes in participants of the Atherosclerosis Risk in Communities Study. *JAMA Cardiol* 2018;3:200–206.
95. Nanna MG, Navar AM, Zakrofsky P, Xiang Q, Goldberg AC, Robinson J, Roger VL, **Virani SS**, Wilson PWF, Ellassal J, Lee LV, Wang TY, Peterson ED. Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the Patient and Provider Assessment of Lipid Management Registry. *JAMA Cardiol* 2018 [Epub ahead of print].
96. Wang Y, Jia L, Hu Z, **Entman ML**, Mitch WE, Wang Y. AMP-activated protein kinase/myocardin-related transcription factor-A signaling regulates fibroblast activation and renal fibrosis. *Kidney Int* 2018;93:81–94.
97. Rebholz CM, Selvin E, Liang M, **Ballantyne CM**, **Hoogeveen RC**, Aguilar D, McEvoy JW, Grams ME, Coresh J. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. *Kidney Int* 2018;93:252–259.
98. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, on behalf of the; CANTOS Trial Group [Collaborators (113): Ridker P, Lorenzatti A, Krum H, ..., **Ballantyne C**, ...]. Effect of interleukin-1 $\beta$  inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet* 2017;390:1833–1842.
99. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, on behalf of the CANTOS Trial Group [Collaborators (56): Ridker PM, MacFadyen JG, Everett BM, ..., **Ballantyne C**, ...]. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet* 2018;391:319–328.
100. Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygård O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, Cooper-DeHoff R, Johnson J, Scholz M, Beutner F, Thiery J,



- Smith JG, Vilmundarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leiherer A, Saely CH, Drexel H, Mündlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hofer IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagström E, Wallentin L, Åkerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczeklik W, Kaczor M, Sanak M, **Virani SS, Ballantyne CM**, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS, on behalf of the GENIUS-CHD consortium, Krämer BK, Scharnagl H, Fliser D, März W, Speer T. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. *Lancet Diabetes Endocrinol* 2017;5:534–543.
101. **Saeed A**, Kampangkaew J, **Nambi V**. Prevention of cardiovascular disease in women. *Methodist Deakey Cardiovasc J* 2017;13:185–192.
102. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR, for the EBBINGHAUS Investigators [Collaborators (461): Wittert G, Begg A, Simpson R, ... **Ballantyne C**, ...]. Cognitive function in a randomized trial of evolocumab. *N Engl J Med* 2017;377:633–643.
103. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, **Ballantyne C**, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, for the CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;377:1119–1131.
104. HPS3/TIMI55–REVEAL Collaborative Group [Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ; Collaborators (2325): Jiang L, Armitage J, Haynes R, ..., **Ballantyne C**, ...]. Effects of anacetrapib in patients with atherosclerotic vascular disease. *N Engl J Med* 2017;377:1217–1227.
105. Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, Saleheen D, Emdin C, Alam D, Alves AC, Amouyel P, Di Angelantonio E, Arveiler D, Assimes TL, Auer PL, Baber U, **Ballantyne CM**, Bang LE, Benn M, Bis JC, Boehnke M, Boerwinkle E, Bork-Jensen J, Bottinger EP, Brandslund I, Brown M, Busonero F, Caulfield MJ, Chambers JC, Chasman DI, Chen YE, Chen YI, Chowdhury R, Christensen C, Chu AY, Connell JM, Cucca F, Cupples LA, Damrauer SM, Davies G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dubé MP, Ebeling T, Eiriksdottir G, Esko T, Farmaki AE, Feitosa MF, Ferrario M, Ferrieres J, Ford I, Fornage M, Franks PW, Frayling TM, Frikke-Schmidt R, Fritsche LG, Frossard P, Fuster V, Ganesh SK, Gao W, Garcia ME, Gieger C, Giulianini F, Goodarzi MO, Grallert H, Grarup N, Groop L, Grove ML, Gudnason V, Hansen T, Harris TB, Hayward C, Hirschhorn JN, Holmen OL, Huffman J, Huo Y, Hveem K, Jabeen S, Jackson AU, Jakobsdottir J, Jarvelin MR, Jensen GB, Jørgensen ME, Jukema JW, Justesen JM, Kamstrup PR, Kanoni S, Karpe F, Kee F, Khera AV, Klarin D, Koistinen HA, Kooner JS, Kooperberg C, Kuulasmaa K, Kuusisto J, Laakso M, Lakka T, Langenberg C, Langsted A, Launer LJ, Lauritzen T, Liewald DCM, Lin LA, Linneberg A, Loos RJJ, Lu Y, Lu X, Mägi R, Malarstig A, Manichaikul A, Manning AK, Mäntyselkä P, Marouli E, Masca NGD, Maschio A, Meigs JB, Melander O, Metspalu A, Morris AP, Morrison AC, Mulas A, Müller-Nurasyid M, Munroe PB, Neville MJ, Nielsen JB, Nielsen SF, Nordestgaard BG, Ordovas JM, Mehran R, O'Donnell CJ, Orho-Melander M, Molony CM, Muntendam P, Padmanabhan S, Palmer CNA, Pasko D, Patel AP, Pedersen O, Perola M, Peters A, Pisinger C, Pistis G, Polasek O, Poulter N, Psaty BM, Rader DJ, Rasheed A, Rauramaa R, Reilly DF, Reiner AP, Renström F, Rich SS, Ridker PM, Rioux

- JD, Robertson NR, Roden DM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sanna S, Sattar N, Schmidt EM, Scott RA, Sever P, Sevilla RS, Shaffer CM, Sim X, Sivapalaratnam S, Small KS, Smith AV, Smith BH, Somayajula S, Southam L, Spector TD, Speliotes EK, Starr JM, Stirrups KE, Stitzel N, Strauch K, Stringham HM, Surendran P, Tada H, Tall AR, Tang H, Tardif JC, Taylor KD, Trompet S, Tsao PS, Tuomilehto J, Tybjaerg-Hansen A, van Zuydam NR, Varbo A, Varga TV, Virtamo J, Waldenberger M, Wang N, Wareham NJ, Warren HR, Weeke PE, Weinstock J, Wessel J, Wilson JG, Wilson PWF, Xu M, Yaghoobkar H, Young R, Zeggini E, Zhang H, Zheng NS, Zhang W, Zhang Y, Zhou W, Zhou Y, Zoledziwska M; CHARGE Diabetes Working Group; EPIC-InterAct Consortium; EPIC-CVD Consortium; GOLD Consortium; VA Million Veteran Program, Howson JMM, Danesh J, McCarthy MI, Cowan CA, Abecasis G, Deloukas P, Musunuru K, Willer CJ, Kathiresan S. Exome-wide association study of plasma lipids in >300,000 individuals. *Nat Genet* 2017;49:1758–1766.
106. **Li N**, Dobrev D. Targeting atrial fibrillation promoting atrial structural remodeling: is this a viable strategy in patients with heart failure? *Naunyn Schmiedeberg's Arch Pharmacol* 2018;391:231–233.
107. Walker KA, **Hoogeveen RC**, Folsom AR, **Ballantyne CM**, Knopman DS, Windham BG, Jack CR Jr, Gottesman RF. Midlife systemic inflammatory markers are associated with late-life brain volume: the ARIC study. *Neurology* 2017;89:2262–2270.
108. **Virani SS**, Akeroyd JM, Ramsey DJ, Deswal A, Nasir K, Rajan SS, **Ballantyne CM**, Petersen LA. Health care resource utilization for outpatient cardiovascular disease and diabetes care delivery among advanced practice providers and physician providers in primary care. *Popul Health Manag* 2018;21:209–216.
109. Wu J, **Wu H**, An J, **Ballantyne CM**, Cyster JG. Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity. *Proc Natl Acad Sci U S A* 2018;115:6786–6791.
110. Fashanu OE, Heckbert SR, Aguilar D, Jensen PN, **Ballantyne CM**, Basu S, **Hoogeveen RC**, deFilippi C, Cushman M, Folsom AR. Galectin-3 and venous thromboembolism incidence: the Atherosclerosis Risk in Communities (ARIC) Study. *Res Pract Thromb Haemost* 2017;1:223–230.
111. Walker KA, Power MC, **Hoogeveen RC**, Folsom AR, **Ballantyne CM**, Knopman DS, Windham BG, Selvin E, Jack CR Jr, Gottesman RF. Midlife systemic inflammation, late-life white matter integrity, and cerebral small vessel disease: the Atherosclerosis Risk in Communities Study. *Stroke* 2017;48:3196–3202.
112. Faza NN, **Virani SS**, **Nambi V**, Shah T. Aberrant course of pacemaker leads: when left is left. *Tex Heart Inst J* 2018;45:52–53.
113. McBride CL, Akeroyd JM, Ramsey DJ, **Nambi V**, Nasir K, Michos ED, Bush RL, Jneid H, Morris PB, Bittner VA, **Ballantyne CM**, Petersen LA, **Virani SS**. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. *Vasc Med* 2018;23:232–240.

## **B. Awards and honors**

1. **Ballantyne**: Houston Chronicle Top Doctors 2017
2. **Ballantyne**: Castle Connaly Top Doctors: Southeast Texas, Castle Connaly Medical Ltd., 2017
3. **Ballantyne**: Castle Connaly Top Doctors in Texas for the Speciality of Cardiovascular Disease, Castle Connolly Medical Ltd., 2017
4. **Ballantyne**: Castle Connaly Top Doctors in America, Castle Connolly Medical Ltd., 2018

5. **Ballantyne:** Selected by his peers for inclusion in Best Doctors in America®, Best Doctors, Inc., Aiken, South Carolina, 2018
6. **Ballantyne:** 2017 Highly Cited Researcher presented by Clarivate Analytics, Web of Science, top 1% of researchers most cited
7. **Entman:** International Academy of Cardiovascular Sciences Lifetime Achievement Award in Cardiovascular Science, Medicine and Surgery, August 2017
8. **Li:** University of Houston Teaching Excellence Award for Group Teaching, 2017–2018
9. **Virani:** Norton Rose Fulbright Faculty Excellence Award, Development of Enduring Educational Materials, Baylor College of Medicine
10. **Virani:** Inducted into Best Doctors database

### **C. Professional organization/association offices held**

1. **Ballantyne:** Chair, LDL: Address the Risk Think Tank, American College of Cardiology
2. **Ballantyne:** Writing Committee, Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, American College of Cardiology
3. **Ballantyne:** Board, American Society for Preventive Cardiology
4. **Ballantyne:** Board, National Lipid Association
5. **Ballantyne:** Scientific Meeting Committee, National Lipid Association
6. **Ballantyne:** Co-chair, Project Review Committee, National Lipid Association
7. **Brunner:** Member, Grant Peer Review Committee, Innovative Project Award (IPA) Committee, American Heart Association
8. **Jones:** Chief Science Officer, National Lipid Association
9. **Virani:** Chair, Leadership Council and Council for the Prevention of Cardiovascular Disease, American College of Cardiology
10. **Virani:** Chair, Research and Publications Committee, PINNACLE Registry, National Cardiovascular Data Registry, American College of Cardiology
11. **Virani:** Member, LDL: Address the Risk Think Tank, American College of Cardiology
12. **Virani:** Member, Guideline Tool Work Group, 2018 ACC/AHA Cholesterol Guideline, American College of Cardiology
13. **Virani:** Member, Research to Practice (R2P) Initiative Work Group, National Cardiovascular Data Registry, American College of Cardiology
14. **Virani:** Topic Coordinator (Prevention), Annual Scientific Session Program Committee, American College of Cardiology
15. **Virani:** Chair, Heart Disease and Stroke Statistics Committee, American Heart Association
16. **Virani:** Member, EPI Leadership Committee, Council on Epidemiology and Prevention, American Heart Association
17. **Virani:** Board of Directors, American Society of Preventive Cardiology
18. **Wu:** Member, Grant Peer Review Committee, Lipids BSc 2 Committee, American Heart Association

### **D. Editorial board memberships and editorial positions**

1. **Ballantyne:** Editorial Director, lipidsonline.org
2. **Ballantyne:** Editorial Board, *Circulation*
3. **Ballantyne:** Editorial Board, *Clinical and Translational Science*
4. **Ballantyne:** Editorial Board, *Current Cardiology Reviews*

5. **Ballantyne:** Editorial Board, *Future Lipidology*
6. **Cruz:** Editorial Board, *Thrombosis & Haemostasis: Research*
7. **Foreyt:** Editorial Board, *American Journal of Health Behavior*
8. **Foreyt:** Editorial Board, *American Journal of Health Promotion*
9. **Foreyt:** Editorial Board, *American Journal of Lifestyle Medicine*
10. **Foreyt:** Editorial Board, *Childhood Obesity*
11. **Foreyt:** Editorial Board, *Nutrition Today*
12. **Foreyt:** Editorial Board, *Obesity and Weight Management*
13. **Foreyt:** Editorial Board, *Obesity Research and Clinical Practice*
14. **Jones:** Associate Editor, *Journal of Clinical Lipidology*
15. **Pi:** Guest Editor, *Oxidative Medicine and Cellular Longevity*
16. **Pi:** Review Editor, *Arteriosclerosis, Thrombosis and Vascular Biology*
17. **Pi:** Review Editor, *Frontiers*
18. **Pi:** Review Editor, *Journal of Molecular and Cellular Cardiology*
19. **Pi:** Review Editor, *Nature Communications*
20. **Virani:** Associate Editor, Innovations, ACC.org
21. **Virani:** Editorial Team Member and Chair for Digital Strategy, Cardiovascular Prevention Section, ACC.org (educational web portal for the American College of Cardiology)
22. **Virani:** Advisory Board, *Advances in Therapy*
23. **Virani:** Guest Editor, *Circulation*
24. **Virani:** Editorial Board, *Circulation*
25. **Virani:** Section Editor, "Coronary Heart Disease," *Current Atherosclerosis Reports*
26. **Virani:** Associate Editor, *Journal of Clinical Lipidology* (Section specialty: Cardiovascular Outcomes and Guidelines)
27. **Virani:** Associate Editor, *Global Heart* (Official Journal of the World Heart Federation)
28. **Wu:** Guest Associate Editor, *Frontiers in Immunology* (T cell biology in adipose tissue)
29. **Wu:** Editorial Board, *Archives of Inflammation*
30. **Wu:** Editorial Board, *International Journal of Hematology Research*
31. **Wu:** Editorial Board, *Journal of Pediatric Endocrinology*
32. **Wu:** Editorial Board, *JSM Atherosclerosis*
33. **Wu:** Editorial Board, *SM Journal of Endocrinology and Metabolism*

#### **E. Other significant accomplishments**

1. **Brunner:** Reviewer, Biomedical Imaging Technology Study Section–A, Center for Scientific Review, NIH, Bethesda, MD
2. **Brunner:** Reviewer and "Application Chair," ZRG1 MOSS-D (82) A NIH study Section (Musculoskeletal, Oral, Skin, Rheumatology and Rehab Sciences [R15])
3. **Brunner:** Invited Keynote Speaker, "Skeletal Calf Muscle Perfusion Measurement To Assess Peripheral Arterial Disease," 10th European Symposium Of Vascular Biomaterials Strasbourg, France
4. **Brunner:** Invited Guest Speaker, Special Seminar on Magnetic Resonance Imaging in Peripheral Artery Disease, Penn State Heart and Vascular Institute, Penn State Health Milton S. Hershey Medical Center, Hershey, PA
5. **Brunner:** Invited Speaker, "Inflammation, Microvascular Perfusion, and Peripheral Arterial Disease," George and Angelina Kostas Research Center for Cardiovascular Nanomedicine, Annual International Meeting, Houston, TX
6. **Brunner:** Invited Presenter, "Inflammation, Microvascular Perfusion and Peripheral Arterial Disease," American Heart Association Reverse Site Visit as one of the 9

- finalists the Clinical Project of the Strategically Focused Vascular Disease Research Network (Center Director: John P. Cooke), Dallas, TX
7. **Brunner:** Invited Presenter, "Advanced Physics, Fourier Transformation Parallel Imaging, and MRI Safety," Houston Methodist Cardiovascular Magnetic Resonance Workshop, DeBakey Institute for Cardiovascular Education & Training, Houston Methodist Hospital, Houston, TX
  8. **Brunner:** Didactic Lectures, Cardiovascular sciences graduate course (GS-CS-411)—Cardiovascular Physiology, and Structural Basis of Human Diseases (GS-SB-423), BCM
  9. **Brunner:** Poster Judge, 3rd Annual VA Research Poster Session. Michael E. DeBakey VA Medical Center, Houston, TX
  10. **Cruz:** Invited lecture, "A Novel Target to Prevent Microvascular Thrombosis and Multiple Organ Dysfunction Syndrome in Sepsis," Microbiology & Immunology, UTMB
  11. **Cruz:** Invited lecture, "Novel Targets to Prevent Microvascular Thrombosis in Sepsis," CVRI seminar series, BCM
  12. **Li:** Ad hoc reviewer, 2018 NIH ESTA Study Section
  13. **Li:** Ad hoc reviewer, 2017 Farouk Jabre Research Proposal
  14. **Li:** Invited lecture, "The inflammasome in AF," Heart Failure Association Winter Meeting on Translational Heart Failure Research 2018, Les Diablerets, Switzerland
  15. **Li:** Invited lecture, "Emerging role of the inflammasome as novel target in atrial fibrillation therapy," American Heart Association Scientific Session 2017, Anaheim, CA
  16. **Li:** Invited lecture, "Role of Cardiac Inflammasome in the Pathogenesis of Atrial Fibrillation," IMBS 2018 Research Conference and Retreat, BCM
  17. **Li:** Invited lecture, "Emerging Role of Cardiac Inflammasome In the Development of Atrial Fibrillation," CVRI seminar series, BCM
  18. **Li:** Invited conference moderator, Ion Channels and Arrhythmias session, American Heart Association Basic Cardiovascular Sciences (BCVS) Council Scientific Sessions 2017, Portland, OR
  19. **Pi:** Invited lecture, "A secret life of the vascular endothelium," Society of Chinese Bioscientists in America—Texas Chapter annual symposium
  20. **Pi:** Invited lecture, "The role of vascular endothelium in metabolic health," Texas Heart Institute seminar series
  21. **Pi:** Course organizer, TBMM graduate program Bench to Bedside Series, Term 3: Current topics in translational cardiovascular medicine
  22. **Pi:** Seminar host, TBMM graduate program Bench to Bedside Series. "Ahoj CRISPR" presented by Dr. Joseph M. Miano, University of Rochester
  23. **Pi:** Poster judge, CVRI 2018 Symposium, BCM
  24. **Pi:** Grant proposal reviewer, CVRI Pilot Awards, BCM
  25. **Pi:** Reviewer of graduate student candidates, Molecular Physiology & Biophysics Graduate Program, BCM
  26. **Pi:** Member of Graduate student committee for Nirva Mumcuyan, Developmental Biology Program, BCM
  27. **Virani:** Invited speaker, Global Cardiovascular Disease Prevention webinars in Indonesia, Malaysia, Vietnam, and UAE
  28. **Wu:** Member, NIH/NIGMS SCORE Grant Review Panel
  29. **Wu:** Member, American Heart Association Grant Peer Review Committee, Lipids BSc Committee
  30. **Wu:** Member, Immunology Graduate Program Qualifying Exam Committee, BCM
  31. **Wu:** Member, Immunology Graduate Admission Committee, BCM
  32. **Wu:** English language interviewer, J1 visa candidates, BCM
  33. **Wu:** Poster judge, CVRI 2018 Symposium, BCM

34. **Wu:** Didactic Lecture, Cardiovascular Disease and Pathology (GS-CS-412), BCM
35. **Wu:** Judge, Young Investigator Award Oral Presentation, 2018 CAAC-MPVD-ATVB Symposium, San Francisco, CA

## **E. Grants**

1. **Ballantyne (co-PI):** Profiling Cardiovascular Events and Biomarkers in the Very Old to Improve Personalized Approaches for the Prevention of Cardiac and Vascular Disease; NIH/NHLBI (R01); annual direct costs \$549,802 (09/01/2016–08/31/2020)
2. **Ballantyne (coinvestigator):** Atherosclerosis Risk in Communities (ARIC) Study–Field Centers; NIH; annual direct costs \$311,673 (11/15/2016–11/14/2021)
3. **Ballantyne (coinvestigator):** Monocyte Activation and the Role of CD11c in Obesity-Linked Metabolic Syndrome; NIH/NHLBI (R01); annual direct costs \$241,769 (04/01/2015–03/31/2020)
4. **Ballantyne (coinvestigator):** Diabetes and Prediabetes in Older Adults; NIH/NIDDK (R01); annual direct costs \$36,371 (01/01/2016–12/31/2020)
5. **Ballantyne (coinvestigator):** miRNAs, Whole Diet, and Coronary Heart Disease; NIH/NHLBI (R56); total direct costs \$12,147 (09/01/2016–08/31/2018)
6. **Ballantyne (coinvestigator):** Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: \$486,957 (01/01/2014–12/31/2017)
7. **Ballantyne (PI):** The Familial Hypercholesterolemia Foundation Cascade-FH Registry; Duke University; total direct costs \$20,000 (07/01/2014–06/30/2019)
8. **Ballantyne (PI):** Measurement of Galectin-3 at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs \$31,500 (03/14/2014–07/31/2018)
9. **Ballantyne (PI):** hsTroponin Screening at Visit 4 and Visit 5 for the Full ARIC Cohort; Abbott Laboratories; total direct costs \$371,965 (05/12/2014–05/11/2019)
10. **Ballantyne (PI):** A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD); Akcea Therapeutics; total direct costs \$172,510 (02/28/2017–02/27/2020)
11. **Ballantyne (PI):** A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients with Hypertriglyceridemia and Established Cardiovascular Disease; Akcea Therapeutics; total direct costs \$206,886 (03/08/2018–03/07/2021)
12. **Ballantyne (PI):** A Multicenter, Controlled, Open-Label Extension (OLE) Study to Assess the Long-Term Safety and Efficacy of AMG-145; Amgen, Inc; total direct costs \$43,965 (06/01/2013–02/08/2018)
13. **Ballantyne (PI):** GAUSS-3A—Double-Blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of an HMG-CoA Reductase Inhibitor due to Muscle Related Side Effects; Amgen, Inc; total direct costs \$60,085 (02/18/2014–03/21/2018)
14. **Ballantyne (PI):** A Multicenter, Open-Label, Single-Arm, Extension Study to Assess Long-Term Safety of Evolocumab Therapy in Patients with Clinically Evident Cardiovascular Disease; Amgen Inc; total direct costs \$45,670 (08/17/2016–12/31/2021)
15. **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled, Multicenter Long-

Term Safety and Tolerability Study of ETC 1002 in Patients with Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy; Esperion Therapeutics; total direct costs \$62,963 (06/27/2016–06/29/2018)

16. **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant; Esperion Therapeutics; total direct costs \$40,614 (05/17/2017–04/30/2020)
17. **Ballantyne (PI):** A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of bempedoic acid (ETC1002) 180 mg/day as add-on to ezetimibe therapy in patients with elevated LDL-C; Esperion Therapeutics; total direct costs \$29,253 (06/07/2017–04/25/2018)
18. **Ballantyne (PI):** A Randomized, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed-dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy; Esperion Therapeutics; total direct costs \$21,194 (11/29/2017–11/17/2018)
19. **Ballantyne (PI):** A Multicenter Open-Label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg; Esperion Therapeutics; total direct costs \$22,400 (08/07/2017–12/31/2019)
20. **Ballantyne (PI):** A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events among Stable Post-Myocardial Infarction Patients with Elevated hsCRP; Novartis Pharmaceutical Company; total direct costs \$125,877 (04/25/2011–12/31/2020)
21. **Brunner (PI):** Microvascular Perfusion Assessment of Ischemic Diabetic Ulcers Using MRI; NIH/NHLBI (K25); annual direct costs \$154,958 (12/01/2014–12/31/2019)
22. **Brunner (PI):** MRI Based Calf Muscle Perfusion to Assess Patients with Symptomatic PAD; NIH/NHLBI (R01); annual direct costs \$350,417 (08/01/2017–07/31/2022)
23. **Brunner (coinvestigator):** Biomarker Guided Therapies in Stage A/B Heart Failure; VA Office of Research and Development; annual direct costs \$14,189 (04/01/2014–03/31/2019)
24. **Cieslik (co-PI):** Trafficking Leukocytes in the Aging Mouse Heart: in Vivo MRI and Flow Cytometry; BCM Cardiovascular Research Institute Pilot Award (09/01/2017–06/30/2018)
25. **Cieslik (coinvestigator):** Role of Blood-Borne Fibroblast Precursors in Ischemic Cardiomyopathy; NIH/NHLBI (R01); annual direct costs \$250,000 (07/01/2007–11/30/2017)
26. **Cieslik (PI):** A Spontaneous Mutation in *Nnt* Gene Promotes Cardiac Fibrosis in the Aging Heart; The Medallion Foundation; total direct costs \$50,000 (07/01/2015–12/31/2018)
27. **Cruz (multi-PI):** Microvascular Thrombosis in Systemic Inflammation; NIH/NIGMS (R01); annual direct costs \$220,000 (09/25/2014–05/31/2019)
28. **Cruz (co-PI):** Role of Vimentin in Thrombosis and Stroke; NIH/NINDS (R01); annual direct costs \$381,958 (09/01/2016–05/31/2021)
29. **Entman (PI):** Role of Blood-Borne Fibroblast Precursors in Ischemic Cardiomyopathy; NIH/NHLBI (R01); annual direct costs \$250,000 (07/01/2007–11/30/2017)
30. **Entman (PI):** Researching the Aging Heart; The Curtis and Doris K. Hankamer Foundation; annual direct costs \$40,000 (01/01/2001–12/31/2018)

31. **Foreyt (PI):** Study of Health Outcomes of Weight-Loss (Look AHEAD) Trial; NIH/NIDDK (U01); annual direct costs \$152,265 (09/01/1999–01/31/2019)
32. **Foreyt (PI):** Vitamin D to Prevent Type 2 Diabetes (D2d Study); NIH/NIDDK (U01); annual direct costs \$45,309 (06/01/2013–01/31/2019)
33. **Hoogeveen (coinvestigator):** Atherosclerosis Risk in Communities (ARIC) Study—Field Centers; NIH/NHLBI; annual direct costs \$311,673 (11/15/2016–11/14/2021)
34. **Hoogeveen (coinvestigator):** Diabetes and Pre-diabetes in Older Adults; NIH/NIDDK (R01); total direct costs \$200,000 (09/01/2016–12/31/2020)
35. **Hoogeveen (coinvestigator):** Endogenous Hormones and Postmenopausal Breast Cancer: Etiologic Insights and Improving Risk Prediction; NIH/NCI; annual direct costs \$76,772 (06/15/2017–03/31/2022)
36. **Hoogeveen (PI):** Relation of Lipoprotein(a) and Small Dense LDL-C (sdLDL-C) to Incident CHD and Stroke: the ARIC Study; Denka Seiken Co, Ltd; annual direct costs \$18,021 (10/01/2010–12/31/2017)
37. **Hoogeveen (PI):** Relationship of Small-Dense LDL Cholesterol (sdLDL-C) and Lp(a) with Progression of Atherosclerosis in the Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin versus Atorvastatin (SATURN) Trial; Denka Seiken Co, Ltd (11/01/2013–12/31/2017)
38. **Hoogeveen (PI):** Lipoprotein Subfractions Study: the ARIC Study; Denka Seiken Co, Ltd; annual direct costs \$56,750 (11/01/2015–08/31/2018)
39. **Jones:** A Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled , Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA Intervention Trial); Amarin Pharmaceuticals; total direct costs \$25,000 (06/01/2012–12/31/2018)
40. **Li (PI):** Inflammasome Mediated Pathogenesis of Atrial Fibrillation; NIH/NHLBI (R56); annual direct costs \$250,000 (09/01/2016–08/31/2018)
41. **Li (PI):** The Role of Inflammasome in the Pathogenesis of Atrial Fibrillation; NIH/NHLBI (R01); annual direct costs \$379,069 (09/01/2017–06/30/2021)
42. **Li (PI):** Transcriptional Regulation of Ryanodine Receptor 2 in Atrial Fibrillation; American Heart Association Scientist Development Grant; annual direct costs \$379,069 (09/01/2017–06/30/2021)
43. **Li (coinvestigator):** Novel Roles of  $FE^{2+}$ , 2-Oxoglutarate-Dependent Dioxygenases in Cardiac Function; NIH/NHLBI (R01); annual direct costs \$250,000 (09/01/2015–08/31/2020)
44. **Li (coinvestigator):** Pitx2 in Atrial Fibrillation; NIH/NHLBI (R01); annual direct costs \$327,304 (02/01/2018–02/28/2023)
45. **Nambi (PI):** Biomarker Guided Therapies in Stage A/B Heart Failure; VA Office of Research and Development; annual direct costs \$14,189 (04/01/2014–03/31/2019)
46. **Nambi (PI):** TIMI 55/REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid-Modification): A Large Scale, Randomized, Placebo-Controlled Trial of the Clinical Effects of Anacetrapib among People with Established Vascular Disease; Brigham and Women's Hospital; total direct costs \$150,000 (11/01/2011–02/28/2019)
47. **Pi (PI):** LRP1 and Endothelial Function; NIH/NHLBI (R01); annual direct costs \$250,000 (08/01/2013–05/31/2019)
48. **Pi (PI):** Signaling in Endothelial Growth and Angiogenesis; NIH/NHLBI (R01); annual direct costs \$250,000 (12/18/2013–12/31/2018)



49. **Trial (coinvestigator):** Role of Blood-Borne Fibroblast Precursors in Ischemic Cardiomyopathy; NIH/NHLBI (R01); annual direct costs \$250,000 (07/01/2007–11/30/2017)
50. **Vijayan (PI):** Serine/Threonine Phosphatases and Platelet Physiology; NIH/NHLBI (R01); annual direct costs \$250,000 (03/01/2013–02/28/2019)
51. **Vijayan (multi-PI):** Microvascular Thrombosis in Systemic Inflammation; NIH/NIGMS (R01); annual direct costs \$220,000 (09/25/2014–05/31/2019)
52. **Vijayan (PI of subcontract to Baylor College of Medicine):** Aspirin-PC for Chemoprevention of Colorectal Cancer; NIH/NCI (R42); annual direct costs \$86,000 (05/01/2017–04/30/2019)
53. **Vijayan (PI):** PP2B Modulates RhoA Activation and Platelet Function by Targeting RhoGDI; American Heart Association; annual direct costs \$70,000 (07/01/2017–06/30/2019)
54. **Virani (PI):** Comparative Effectiveness of Physicians versus Non-physicians for the Delivery of Outpatient Diabetes Care: Implications for Access to Care under the Affordable Care Act; American Diabetes Association; total direct costs: \$486,957 (01/01/2014–12/31/2017)
55. **Virani (PI):** Determining and Targeting Reasons for Low Statin Use to Improve Guideline-Concordant Statin Therapy in High-Risk Patients; VA Merit Award; total direct costs: \$1,097,703 (07/01/2017–06/30/2021)
56. **Wu (PI):** Monocyte Activation and the Role of CD11c in Obesity-Linked Metabolic Syndrome; NIH/NHLBI (R01); annual direct costs \$241,769 (04/01/2015–03/31/2020)
57. **Wu (PI):** ApoCIII, Triglyceride-Rich Lipoproteins and Atherogenesis; American Heart Association; total direct costs \$140,000 (07/01/2016–06/30/2019)
58. **Wu (PI):** Macrophage/Dendritic Cell Activation and Inflammation in Diet-Induced Obesity; American Diabetes Association; annual direct costs \$104,546 (01/01/2017–12/31/2019)
59. **Wu (co-PI):** Imaging Monocyte Tracking into Atherosclerosis and Adipose Tissue in Mice; BCM Cardiovascular Research Institute Pilot Award; total direct costs \$15,000 (09/01/2017–06/30/2018)
60. **Xie (PI):** Novel Roles of  $FE^{2+}$ , 2-Oxoglutarate-Dependent Dioxygenases in Cardiac Function; NIH/NHLBI (R01); annual direct costs \$250,000 (09/01/2015–08/31/2020)
61. **Xie (coinvestigator):** LRP1 and Endothelial Function; NIH/NHLBI (R01); annual direct costs \$250,000 (08/01/2013–05/31/2019)
62. **Xie (coinvestigator):** Signaling in Endothelial Growth and Angiogenesis; NIH/NHLBI (R01); annual direct costs \$250,000 (12/18/2013–12/31/2018)